Recently, Lilly has reached a number of cooperation, and has laid out a number of market targets exceeding 100 billion

In recent years, under the background of the continuous expansion of the pharmaceutical market and the accelerated reshuffle of the industry, domestic and foreign pharmaceutical companies have begun to pay more attention to innovative drugs
.
Affected by this, in order to further promote the research and development of innovative drugs and accelerate the layout of different pipelines, the cooperation between pharmaceutical companies has also become more frequent
.
Among them, it is worth mentioning that recently, some pharmaceutical companies have successively launched a number of cooperation, and laid out a number of drug targets with a market size of over 100 billion
.
For example, on January 18, Eli Lilly announced that it had entered into a global cooperation and exclusive license agreement with Heyu Medicine to further target undisclosed targets in major diseases with unmet medical needs such as cardiometabolic diseases.
Collaborate on the discovery, development and potential commercialization of small molecule drugs
.
It is reported that if Heyu Pharma successfully advances the compound to the end point of the agreement, Eli Lilly will have the right to further develop and commercialize it
.
If Eli Lilly is responsible for clinical development and commercialization, Heyu Pharma has the right to receive potential fees of up to $258 million based on the results of predetermined preclinical, clinical development and commercial milestones, as well as sales tiered royalties arising from the agreement fee
.
The industry believes that the targets of the cooperation between the two parties will focus on other fields such as cardiovascular, metabolism and tumor
.
In terms of coverage, each field has a market size of over 100 billion, and the indications cover a wide range of people
.
This also means that the targets of future cooperation between the two parties have extremely high potential commercial value
.
It is worth noting that, in addition to the cooperation with Heyu Medicine, Lilly also recently announced that it will cooperate with Evotec in the field of drug research and development in the field of metabolic diseases.
The main projects will focus on kidney disease and diabetes
.
It is understood that Evotec will be responsible for the search for potential drug candidates from the identified targets
.
Eli Lilly will reserve the right to select up to five projects under this partnership for subsequent development and commercialization
.
It is worth mentioning that, for this cooperation, Evotec will first receive an advance payment
.
The company will also be eligible for additional payments of up to $180 million per project following a series of milestones in successful development, regulatory clearance and commercialization
.
At the same time, the company also has the opportunity to receive tiered awards based on net product sales, with a potential total value of up to $1 billion
.
In addition, a month ago, Lilly also reached a cooperation with Shanghai Ruige Pharmaceuticals.
The two parties will cooperate closely in preclinical drug development, clinical research and commercialization in the next few years to jointly develop innovative treatments for metabolic diseases.

.
Under the terms of the agreement, Riage Pharma will grant Lilly an intellectual property license, which Lilly may choose to extend
.
Eli Lilly will be responsible for clinical development, manufacturing and commercialization excluding Greater China
.
In addition, Eli Lilly will pay an upfront payment of up to $50 million (in part as an equity investment), while Riage Pharma is eligible for potential future milestone payments of up to $1.
5 billion, as well as tiered licensing on net product sales royalties
.
In general, in recent years, the "marriage" of cooperation between pharmaceutical companies is on the rise, and there are more and more cooperation between large and small companies.
At the same time, the amount of cooperation involved has also been huge
.
At present, the frequent cooperation between Lilly and other companies is actually a microcosm of the development of the industry
.
The industry expects that through more and more cooperation in the future, enterprises can achieve greater complementarity of advantages, and can share risks, flexibly mobilize resources from both parties, better promote research and development, accelerate commercialization, and better benefit more.
many patients
.